A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

NCT04737330 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
28
Enrollment
INDUSTRY
Sponsor class

Stopped Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals